The WACC of Hansa Biopharma AB (HNSA.ST) is 6.9%.
| Range | Selected | |
| Cost of equity | 5.30% - 9.60% | 7.45% |
| Tax rate | 0.10% - 0.10% | 0.10% |
| Cost of debt | 4.00% - 7.00% | 5.50% |
| WACC | 5.0% - 8.8% | 6.9% |
| Category | Low | High |
| Long-term bond rate | 2.5% | 3.0% |
| Equity market risk premium | 5.1% | 6.1% |
| Adjusted beta | 0.16 | 0.66 |
| Additional risk adjustments | 2.0% | 2.5% |
| Cost of equity | 5.30% | 9.60% |
| Tax rate | 0.10% | 0.10% |
| Debt/Equity ratio | 0.41 | 0.41 |
| Cost of debt | 4.00% | 7.00% |
| After-tax WACC | 5.0% | 8.8% |
| Selected WACC | 6.9% | |